GLOBAL LEADERS PANEL DISCUSSION

Jing-Shan “Jennifer” Hu, Ph.D.

Partner Qiming U.S. Healthcare Ventures

Speaker Bio

Dr. Jing-Shan “Jennifer” Hu is currently Partner of Qiming US healthcare Ventures. She brings extensive experience in partnering, licensing, R&D and management from three pharmaceutical multinational companies & two successful start-up and young biotech companies in the U.S. Prior to Qiming, she was VP of Bayer Healthcare and Head of its (External) Innovation Center China, responsible for partnerships for Global Drug Discovery with biotech and academia in Greater China. Before that, she was Director of Licensing & External Research at Merck & Co (MSD)’s for its worldwide licensing and partnering efforts on novel drug candidates and technologies from/with Greater China. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics & VEGF-2 Project Leader. She has been successful in partnering with at least 25 biotech and top academic institutions in both the U.S. and China. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ. She was instrumental at leading a successful and peaceful transition of the community of SAPA-West to Chinese-American BioPharmaceutical Society (CABS) as the President of 2006-2007.

Leming Shi, Ph.D.

Professor, School of Pharmacy, Fudan University

Terry Speed, Ph.D.

Professor, Walter & Eliza Hall Institute of Medical Research in Melbourne

Emeritus Professor, Statistics, University of California at Berkeley

Giulia C. Kennedy, Ph.D.

Chief Scientific Officer, Senior Vice President of Research, Producut and Clinical Development, Veracyte

Speaker Bio

Giulia C. Kennedy is Chief Scientific Officer and Senior Vice President of Research, Product and Clinical Development for Veracyte. Since joining the genomic diagnostics company in 2008, Dr. Kennedy has overseen the development of three commercialized genomic tests that help reduce unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty. The company’s tests are setting new standards in disease diagnosis, where they are changing patient care and obtaining insurance coverage. Through Dr. Kennedy’s scientific leadership, Veracyte continually pushes the boundaries of what is possible in genomic diagnostics, using big data and machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc. Before that, she was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development. Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes. She holds a Ph.D. degree in biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 50 articles in peer-reviewed scientific journals and is a co-inventor on more than 20 patents.

CHAIRS AND COMMITTEE MEMBERS

General Co-Chairs

• Jing Huang, PhD
• Hua Tang, PhD
• Haiyan Huang, PhD
• Ying Lu, PhD

Steering Committee Chairs

• Hua Tang, PhD
• Haiyan Huang, PhD
• Ruixiao Lu, PhD
• Jing Huang, PhD
• Rui (Sammi) Tang, PhD
• Ying Lu, PhD
• Bin Chen, PhD

Program Committee Chairs

• Hua Tang, PhD
• Haiyan Huang, PhD
• Rui (Sammi) Tang, PhD
• Ying Lu, PhD

Organizing Committee Chairs

• Ruixiao Lu, PhD
• Jing Huang, PhD
• Bin Chen, PhD
• Peng Yang, MS

Sponsorship Committee Chairs

• Rui (Sammi) Tang, PhD
• Ruixiao Lu, PhD
• Zhanzhi Hu, PhD

Program Committee Members

• Hao Chen, UC Davis
• Chao Cheng, Dartmouth College
• Rui JIang, Tsinghua University
• Pei Wang, Icahn Medical School at Mount Sinai, New York
• Wenyi Wang, MD Anderson Cancer Center
• Zhijin Wu, Brown University
• Nancy Zhang, University of Pennsylvania
• Shihua Zhang, Chinese Academy of Science
• Lei Zhou, Amgen
• Liang Fang, Gilead Sciences
• Qinghua Song, Gilead Sciences
• George Tseng, University of Pittsburgh
• Jie Peng, University of California, Davis
• Aarthi Balasubramanyam, Roche Sequencing Solutions
• Jing Shen, Gilead Sciences
• Rui (Sammi) Tang, Vertex
• Jing Huang, Veracyte
• Yaogang Wang,Tianjin Medical University

Organizing Committee Members

• Yanli (Sunny) Fan, University of California, Berkeley
• Li Ma, Stanford University
• George Shan, University of California, Berkeley
• Mu Zhou, Stanford University
• Xiaobo Wan, University of California, San Francisco
• Bing Hu, University of California, San Francisco
• Bo Zhou, Stanford University
• Shuping Fu, Nanjing University of Chinese Medicine
• Weiwei Wang, Ancestry
• Chenling Xiong, University of California, San Francisco
• Ke Liu, University of California, Berkeley
• Baoming Nie, Ardelyx

Registration Fees